Introduction {#S1}
============

The expression of insecticidal proteins from *Bacillus thuringiensis* (Bt toxins) has proven to be a valuable strategy for agricultural pest management^[@R1]^. Bt toxin-producing crops have been widely adopted in agriculture with substantial economic and environmental benefits^[@R2]^, and have increased global agricultural productivity by an estimated \$78 billion from 1996 to 2013^[@R3]^. Unfortunately, Bt toxin resistance has evolved among insect pests and threatens the continued success of this strategy for pest control^[@R4]^. While resistance management strategies have been developed, including the use of multiple Bt toxins and preserving susceptible alleles in insect populations, the evolution of insect resistance to Bt toxins remains the most serious current threat to sustaining the gains offered by transgenic crops^[@R4]^.

Bt toxins interact with protein receptors on the surface of insect midgut cells, leading to pore formation in the cell membrane and cell death^[@R5]^. Bt toxin resistance is commonly associated with the mutation, down-regulation, or deletion of these receptors^[@R2]^. We hypothesized that it might be possible to overcome Bt toxin resistance by evolving novel Bt toxins that bind with high affinity to new gut cell receptor proteins in insects. If successful, such an approach has the potential to alter toxin specificity, improve toxin potency, and bypass receptor-related resistance mechanisms.

Here we used phage-assisted continuous evolution (PACE) to rapidly evolve Bt toxins through \> 500 generations of mutation, selection, and replication to bind a receptor expressed on the surface of insect midgut cells. PACE-derived Bt toxins bind the new receptor with high affinity and specificity, induce target receptor-dependent lysis of insect cells, and enhance the insecticidal activity against both sensitive and Bt-resistant insect larvae up to 335-fold. Collectively, these results establish an approach to overcoming Bt toxin resistance and also provide a new platform for the rapid evolution of other protein-binding biomolecules.

Development of protein-binding PACE {#S2}
===================================

PACE has mediated the rapid laboratory evolution of diverse protein classes including polymerases, proteases, and genome-editing proteins, yielding variants with highly altered activities and specificities^[@R6]--[@R12]^. While PACE has not been previously used to evolve protein-binding activity, we speculated that the bacterial 2-hybrid system^[@R13]^ could serve as the basis of a protein-binding PACE selection ([Fig. 1a](#F1){ref-type="fig"}). Target binding results in localization of RNA polymerase upstream of a reporter gene, initiating gene expression. To adapt this system into a protein-binding selection for PACE, we envisioned that protein:target binding could instead activate the expression of the filamentous bacteriophage gene III, which is required for the infectivity of progeny phage^[@R6]^ ([Fig. 1b](#F1){ref-type="fig"}).

To maximize the sensitivity of the bacterial 2-hybrid, we extensively optimized parameters including (i) transcriptional activation and DNA-binding domains, (ii) protein expression level, (iii) interaction binding affinity, (iv) DNA-binding domain multivalency state, (v) reporter gene ribosome-binding site, (vi) operator--promoter distance, (vii) RNA polymerase--promoter affinity, and (viii) DNA-binding domain--bait linker length. While the previously described bacterial 2-hybrid system yielded a 17-fold increase in transcriptional activation using a model high-affinity interaction (HA4 monobody binding to the SH2 domain of ABL1 kinase)^[@R14]^, our optimized system enhanced transcriptional activation \> 200-fold using the same interaction ([Extended Data Figs. 1](#F6){ref-type="fig"}--[3](#F8){ref-type="fig"}). This system consisted of the *E. coli* RNA polymerase omega subunit (RpoZ) as the activation domain, the 434 phage cI repressor as the DNA-binding domain, and an optimized P~lacZ~-derived promoter (P~lacZ-opt~) to drive reporter transcription. Together, these results extend and improve previously described bacterial systems^[@R13]^ that transduce protein-target binding into gene expression in a manner that can be tuned by the researcher.

The HA4 monobody binds to the SH2 domain of ABL1 kinase (K~d~ = 7 nM)^[@R14]^. The mutant HA4 Y87A monobody binds the ABL1 SH2 domain with 100- to 1,000-fold weaker affinity^[@R14]^. Whereas wild-type HA4 monobody fused to RpoZ in the presence of 434cI-SH2 resulted in potent transcriptional activation in our optimized bacterial 2-hybrid system, transcriptional activation using HA4~Y87A~ was negligible ([Fig. 2a](#F2){ref-type="fig"}). Similarly, selection phage (SP) expressing the *rpoZ-HA4* fusion robustly propagate using host cell strains carrying accessory plasmids (APs) expressing the *434cI-SH2* fusion, whereas an SP encoding *rpoZ-HA4~Y87A~* did not support phage propagation. These findings demonstrate that the Y87A mutant HA4 monobody does not support gene III expression or phage propagation ([Extended Data Fig. 3](#F8){ref-type="fig"}).

To validate protein-binding PACE, we challenged the system to evolve a functional SH2-binding monobody starting from the HA4~Y87A~ mutant. To revert the HA4~Y87A~ mutant back to a Tyr87 protein requires three adjacent point mutations (GCG to TAT or TAC). The *rpoZ-HA4~Y87A~* SP was propagated during PACE for 66 h in the absence of selection pressure (i.e., allowing evolutionary drift^[@R9]^), before engaging selection pressure by changing the host cell strain to one requiring SH2 binding-dependent phage propagation ([Fig. 2b](#F2){ref-type="fig"}). Under selection pressure, control lagoons that previously experienced neither drift nor mutagenesis, or that experienced only mutagenesis, quickly lost their SPs encoding the evolving monobody population (phage "wash out"). In contrast, lagoons subjected to both drift and mutagenesis dropped markedly in phage titer for the first 12 h, but recovered over the next 24 h ([Fig. 2c](#F2){ref-type="fig"}). Sequence analysis of eight phage clones surviving 48 h of PACE revealed that all eight evolved either Tyr or Trp at HA4 position 87 ([Fig. 2c](#F2){ref-type="fig"}), either of which restored transcriptional activation ([Extended Data Fig. 3](#F8){ref-type="fig"}). These results demonstrate that protein-binding PACE can rapidly evolve proteins with target affinity, even when multiple mutations are required to gain protein-binding activity.

Bt toxin target receptor design {#S3}
===============================

Binding of Bt toxins to protein receptors on insect midgut cells is a critical event in the mechanism of insecticidal activity^[@R5],[@R15]^. To develop a strategy to overcome Bt toxin resistance, we sought to evolve Cry1Ac, a widely used Bt toxin, to bind TnCAD, an insect cell membrane cadherin-like receptor from cabbage looper (*Trichoplusia ni*) that is not natively targeted by wild-type Cry1Ac (see [Supplementary Discussion](#SD1){ref-type="supplementary-material"}). *T. ni* has developed Bt resistance in agricultural settings and has been widely studied for insect resistance to Bt toxins^[@R2]^.

Prior studies of Cry1Ac binding to cadherin-like receptor proteins from Lepidoptera identified multiple putative toxin binding regions (TBRs) in the cadherin^[@R16],[@R17]^. The homologous region of TBR in TnCAD differs from that of cadherin-like proteins from other lepidopteran species at seven amino acid positions ([Extended Data Fig. 4](#F9){ref-type="fig"}). To create an evolutionary stepping-stone from cadherin-like proteins that bind Cry1Ac to TnCAD, three residues (F1433, S1436, and A1437) from the TBR of four other lepidopteran species^[@R18]--[@R21]^ were introduced into TnCAD, resulting in an artificial receptor fragment designated TnTBR3 ([Extended Data Fig. 4](#F9){ref-type="fig"}). We constructed APs expressing various TnTBR3 fragments fused to 434cI and assessed transcriptional activation levels in the presence of various domains of Cry1Ac fused to RpoZ ([Extended Data Fig. 4](#F9){ref-type="fig"}). Only Cry1Ac containing three domains of the active toxin (residues 1-609) showed weak binding activity for TnTBR3 fragment 3 (TnTBR3-F3) ([Extended Data Fig. 4](#F9){ref-type="fig"}). An SP carrying the *rpoZ-Cry1Ac* fusion gene replicated \~100-fold in a host strain carrying the TnTBR3-F3 AP after propagation overnight, whereas a control SP lacking the *rpoZ-Cry1Ac* fusion did not replicate ([Extended Data Fig. 4](#F9){ref-type="fig"}). These observations identified TnTBR3-F3 as a promising evolutionary stepping-stone to serve as a starting target for continuous evolution in PACE.

Evolution of Cry1Ac to bind TnCAD {#S4}
=================================

We performed 528 h of PACE on Cry1Ac in four segments while varying mutagenesis levels and selection stringency ([Fig. 3a](#F3){ref-type="fig"}). For the first two segments (0--144 h, and 144--276 h), the AP expressed the TnTBR3-F3 stepping-stone target fused to 434cI. For the final two segments of PACE (276--396 h, and 396--528 h), the AP expressed the TnCAD-F3 final target fused to 434cI. To enhance mutagenesis, we used the moderate-potency mutagenesis plasmid MP4^[@R12]^ during PACE for binding to TnTBR3-F3 (PACE segments 1 and 2) in an effort to decrease the likelihood of accessing early mutations that could impair essential features of Cry1Ac beyond target receptor binding. During the final two PACE segments for binding to TnCAD-F3 (PACE segments 3 and 4) we used MP6, which induces a greater mutation rate and broader mutational spectrum than MP4^[@R12]^, as phage washout consistently occurred during TnCAD-F3 PACE attempts with MP4, suggesting that higher levels of mutagenesis were required to access rare Cry1Ac mutational combinations that conferred binding to the final TnCAD-F3 target. We increased selection stringency during PACE by increasing lagoon flow rates and reducing the number of TnTBR3-F3 or TnCAD-F3 fragments participating in Cry1Ac variant recognition ([Fig. 2a](#F2){ref-type="fig"}, [Extended Data Fig. 3](#F8){ref-type="fig"}). Phage surviving 528 h of PACE experienced on average 511 generations of mutagenic replication under selection conditions^[@R6]^.

Sequencing of individual clones at the end of the first PACE segment (144 h; four copies of TnTBR3-F3 per P~lacZ-opt~ promoter) revealed a strong consensus of two coding mutations in *Cry1Ac*, and one coding mutation in *rpoZ* ([Extended Data Fig. 5](#F10){ref-type="fig"}). The three mutations together resulted in 11-fold higher transcriptional activation than that of the wild-type *rpoZ-Cry1Ac* fusion. At the end of the second segment (276 h; two copies of TnTBR3-F3 per P~lacZ-opt~ promoter), even greater degrees of transcriptional activation were observed, up to 20-fold higher than the level resulting from the starting fusion protein ([Fig. 3b](#F3){ref-type="fig"}, [Extended Data Fig. 5](#F10){ref-type="fig"}). At the end of third segment (396 h; four copies of TnCAD-F3 per P~lacZ-opt~ promoter), Cry1Ac variants evolved with greatly enhanced apparent affinity for TnCAD-F3 ([Fig. 3c](#F3){ref-type="fig"}, [Extended Data Fig. 5](#F10){ref-type="fig"}). Whereas wild-type Cry1Ac could not detectably activate transcription when challenged to bind TnCAD-F3, single Cry1Ac variants emerging from a total of 384 h of PACE robustly activated transcription up to 210-fold above background in the absence of Cry1Ac variant expression. The end of the fourth segment (528 h; one copy of TnCAD-F3 per P~lacZ-opt~ promoter) yielded Cry1Ac mutants that could activate transcription when challenged to bind TnCAD-F3 by up to 500-fold ([Fig. 3c](#F3){ref-type="fig"}, [Extended Data Fig. 5](#F10){ref-type="fig"}), consistent with strong binding to the TnCAD-F3 final target.

Characterization of evolved Cry1Ac variants {#S5}
===========================================

DNA sequencing of individual clones surviving 528 h of PACE revealed a number of consensus genotypes carrying up to 16 mutations per clone out of 22 consensus mutations, most of which localize to domain II, the predicted cadherin-binding domain of Cry1Ac ([Extended Data Fig. 4](#F9){ref-type="fig"}, [5](#F10){ref-type="fig"}). To illuminate the evolution trajectories en route to TnCAD-F3 binding activity, we analyzed all lagoon samples, by high-throughput DNA sequencing using both shorter-read (Illumina) and longer-read (Pacific Biosciences) methods ([Extended Data Fig. 6](#F11){ref-type="fig"}). These efforts identified 25 mutations commonly occurring over the 528 h of PACE ([Extended Data Fig. 5](#F10){ref-type="fig"}, [6](#F11){ref-type="fig"}). Oligotyping analysis^[@R22]^ of the long-read data revealed plausible evolutionary trajectories over the entire course of the experiment ([Fig. 3d, e](#F3){ref-type="fig"}). While PACE does not explicitly promote recombination as a mechanism of gene diversification, we observed multiple putative recombination events during the course of Cry1Ac evolution ([Fig. 3e](#F3){ref-type="fig"}). These recombination events, which we presume arose from multiple phage occasionally infecting the same host cell, yielded seminal, highly functional new variants.

Based on our mutational analysis, we designed and synthesized consensus Cry1Ac variants containing the most commonly observed mutations ([Fig. 4a, b](#F4){ref-type="fig"}). Purified activated Cry1Ac variants encoding PACE-derived consensus mutations bind very strongly (K~d~ = 18--34 nM) to a TnCAD fragment containing the TBR (TnCAD-FL; [Extended Data Fig. 4](#F9){ref-type="fig"}) by ForteBio bio-layer interferometry analysis, with evolved Cry1Ac variants C03 and C05 exhibiting the highest binding affinities ([Fig. 4a](#F4){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In contrast, wild-type Cry1Ac exhibited no significant affinity for TnCAD-FL (K~d~ \> 1 mM) under the same conditions. These results together establish the ability of protein-binding PACE to rapidly evolve extensively mutated proteins with high target affinity.

Cry1Ac is proteolytically activated in the insect midgut^[@R2]^. The evolved consensus mutants, however, exhibited extensive proteolysis by trypsin under conditions in which the wild-type Cry1Ac was cleanly cleaved into its active form ([Fig. 4c](#F4){ref-type="fig"}). Thermal melting studies confirmed this reduced stability (consensus variants: T~m~ = \~45 °C; wild-type Cry1Ac: T~m~ = 71 °C; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Despite this lower stability, trypsin-activated consensus variants robustly killed Sf9 cells expressing TnCAD, whereas wild-type Cry1Ac did not exhibit toxicity ([Fig. 4d](#F4){ref-type="fig"}). Moreover, these consensus evolved Cry1Ac mutants showed insecticidal activity in *T. ni* larvae, although they were less potent than wild-type Cry1Ac ([Fig. 4e](#F4){ref-type="fig"}).

We hypothesized that a subset of the consensus mutations were impairing apparent toxin potency against insect larvae by decreasing Cry1Ac stability and thus promoting degradation in insect gut. We generated Cry1Ac variants containing combinatorial reversions of the identified consensus mutations, with a focus on mutations that arose during early-stage evolution on the stepping-stone target ([Fig. 4b](#F4){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Using this approach, we identified mutations D384Y and S404C, two mutations that arose early during PACE against the TnTBR3 stepping-stone target ([Fig. 3d, 3e](#F3){ref-type="fig"}, [5a](#F5){ref-type="fig"}), as the source of reduced protein stability. Variants lacking these two mutations, but containing the other seven consensus C05 mutations, exhibited greatly improved, wild-type-like stability (T~m~ = \~60°C). Variants lacking D384Y and S404C also exhibited proteolytic resistance similar to that of wild-type Cry1Ac, while retaining high binding affinity to TnCAD-FL (K~d~ = 11--41 nM) ([Fig. 5a, b](#F5){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

We assayed the toxicity of two evolved consensus Cry1Ac variants (C05 and C03) and three stabilized evolved consensus Cry1Ac variants (C05s, C03s, and A01s) lacking D384Y and S404C to cultured Sf9 insect cells expressing an ABCC2 receptor (positive control) or TnCAD. The stabilized evolved Cry1Ac variants retain their ability to bind to the ABCC2 receptor, while acquiring the ability to potently kill Sf9 cells expressing TnCAD, in contrast to the ability of wild-type Cry1Ac to only kill cells expressing the ABCC2 receptor, but not cells expressing TnCAD ([Fig. 5c](#F5){ref-type="fig"}).

*In vivo* activity of evolved Cry1Ac variants {#S6}
=============================================

Finally, we assayed the insecticidal activity of the stabilized evolved Cry1Ac variants against Cry1Ac-sensitive *T. ni* larvae when added to their diet. Consistent with the *in vitro* results, the stabilized evolved Cry1Ac variants exhibited substantially increased toxicity to *T. ni* larvae compared with that of the consensus evolved Cry1Ac mutants prior to stabilization ([Fig. 5d](#F5){ref-type="fig"}). Interestingly, the stabilized evolved Cry1Ac variants also exhibited insecticidal potency against susceptible *T. ni* up to 4-fold higher than that of wild-type Cry1Ac, suggesting that the evolved affinity of the toxins to a new receptor may augment their insecticidal potency, even against insects susceptible to wild-type Cry1Ac. These results also suggest that the evolution of Bt toxins that to recognize novel receptors could expand the range of insects that can be targeted by Bt toxins, consistent with previous *in vitro* studies^[@R23],[@R24]^ using designed Bt toxin derivatives.

Next we evaluated the insecticidal activity of the stabilized evolved Cry1Ac variants against Cry1Ac-resistant *T. ni* larvae. *T. ni* resistance to Cry1Ac has been genetically mapped to the *ABCC2* transporter gene and down-regulation of expression of *APN1*^[@R25],[@R26]^, and is known to be independent of alteration of the cadherin-like receptor^[@R27]^. In this study, we also confirmed that wild type Cry1Ac does not bind the TBR in TnCAD (see above), consistent with the previous finding that Cry1Ac does not bind TnCAD in *T. ni* midgut cell membranes^[@R25],[@R27],[@R28]^. Indeed, we observed \~1,000-fold lower potency of wild-type Cry1Ac against a Cry1Ac-resistant *T. ni* strain than the potency of wild-type Cry1Ac against susceptible *T. ni*^[@R29]^ ([Fig. 5e](#F5){ref-type="fig"}). Compared to wild-type Cry1Ac, stabilized evolved Cry1Ac variants C05s, C03s, and A01s showed dramatically improved activity against Cry1Ac-resistant *T. ni*, with LC~50~ values up to 335-fold lower than wild-type Cry1Ac ([Fig. 5e](#F5){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}). Importantly, these evolved and stabilized Cry1Ac variants showed similar toxicity in Bt-resistant *T. ni* (LC~50~ = 0.15 ppm) as that of wild-type Cry1Ac in susceptible larvae (LC~50~ = 0.04 ppm) ([Fig. 5e](#F5){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}). Taken together, these results establish that the evolution of novel receptor binding among Bt toxins can overcome Bt toxin resistance in an agricultural pest.

To characterize the species profile of their insecticidal activity, we tested the evolved Cry1Ac variants in diet bioassays against 11 additional agricultural pests: a lepidopteran related to *T. ni* (*Chrysodeixis includes*, soybean looper) that encodes a cadherin-like receptor highly homologous to TnCAD, eight more distantly related lepidopteran pests and three non-lepidopteran pests ([Extended Data Fig. 7](#F12){ref-type="fig"}, [8](#F13){ref-type="fig"}). As expected, the stabilized evolved Cry1Ac variants were more potent than wild-type Cry1Ac against *C. includes*, and comparably potent as wild-type Cry1Ac against the other pests assayed ([Extended Data Fig. 7](#F12){ref-type="fig"}). These results further support the mechanism of action of the PACE-evolved Bt toxins as binding to the cadherin receptor in *T. ni* and the closely related cadherin receptor in *C. includes*. Importantly, the evolved Bt toxins did not acquire new activity against species lacking a receptor homologous to TnCAD. Taken together, these findings demonstrate that an evolved Bt toxin that binds a novel target can potently kill closely related insect pest species, while maintaining a similar overall insect spectrum as the parental Bt toxin.

Discussion {#S7}
==========

Protein-binding PACE rapidly discovered variants of Cry1Ac that bind with high affinity to the novel receptor TnCAD. Perhaps unsurprisingly, we observed a moderate reduction in stability of the evolved variants as compared to wild-type Cry1Ac, as this was not an implicit requirement of the selection. The two mutations that reduced Cry1Ac stability (D384Y and S404C) arose within the first few days of PACE on the stepping-stone target TnTBR3-F3 and were inherited by virtually all subsequent evolved variants ([Fig. 3e](#F3){ref-type="fig"}). It is tempting to speculate that these mutations broadened the substrate scope of Cry1Ac binding to enable downstream protein evolution, at the expense of stability, but were not required once affinity for TnCAD-F3 evolved. Additional affinity measurements of reverted consensus mutations reveal the key roles of E461K, N463S and S582L, which evolved in quick succession during the third PACE segment ([Fig. 3e](#F3){ref-type="fig"}), consistent with their contribution to TnCAD binding. All three mutations lie on the same face of Cry1Ac ([Extended Data Fig. 5c](#F10){ref-type="fig"}), albeit in different domains, further suggestive of potential direct interaction with the cadherin receptor.

Collectively, our findings establish that the laboratory evolution of novel or enhanced Bt toxin-receptor interactions can overcome insect resistance to Bt toxins. This strategy complements existing approaches to limit the incidence of Bt toxin resistance. The "gene pyramiding" strategy for resistance management^[@R30]^, for example, requires the availability of multiple effective toxins with different binding sites in target insects. The refuge strategy^[@R4]^ necessitates that the resistance is a recessive trait and requires compliance by growers. The engineering of Bt toxins to eliminate the reliance on cadherin receptor interaction for toxin oligomerization has been shown to enhance toxicity against resistant strains of several insects, but it also reduces the insecticidal potency of the toxins against sensitive insects^[@R31]^ and may broaden the target specificity of the toxin, creating a potential risk to non-target organisms.

The approach established here enabled targeting of a Bt-resistant pest through the evolution of high-affinity Bt toxin variants that bind a specific target insect protein. In principle, this strategy should be applicable to target a variety of insect pests. While the evolution of insect resistance to an evolved Bt toxin is a likely possibility, this work has the potential to provide access to many new Bt toxins that, individually or in combination, may manage resistance and extend the effectiveness of this important approach to pest control. We also envision that this system may be used to explore potential resistance mechanisms by evolving the receptor in the presence of a Bt toxin, analogous to the recent use of PACE to identify protease inhibitor drug resistance mechanisms^[@R10]^. Finally, we note that the ability of protein-binding PACE to rapidly evolve novel protein-protein interactions may prove useful in the discovery or improvement of protein therapeutics.

METHODS {#S8}
=======

General methods {#S9}
---------------

PCR was performed using PfuTurbo Cx Hotstart DNA polymerase (Agilent Technologies), VeraSeq ULtra DNA polymerase (Enzymatics), or Phusion U Hot Start DNA Polymerase (Life Technologies). Water was purified using a MilliQ water purification system (Millipore). Plasmids and selection phages were constructed using USER cloning (New England Biolabs). Genes were either synthesized as bacterial codon-optimized gBlocks Gene Fragments (Integrated DNA Technologies) or amplified by PCR from native sources. *Cry1ac* was amplified by PCR from the *B. thuringiensis* strain *Bt*\_B107284 and cloned into the *Bt* expression vector pMON101647 using Hot Fusion^[@R32]^ to generate the expression plasmid pMON133051, which served as a template for amplifying *Cry1ac* fragments for constructing PACE vectors. The toxin-binding region from *T. ni* cadherin (A1133-T1582, AEA29692.10), referred to as TnCAD-FL, was synthesized using 45--60-mer oligonucleotides (Integrated DNA Technologies) by overlap extension PCR using KOD Hot Start DNA polymerase (EMD Millipore). The synthetic wild-type TnCAD-FL template was used to generate the TnTBR3-FL fragment via site-directed mutagenesis using the QuikChange II kit according to the manufacturers' instructions. (Agilent Technologies). DNA vector amplification was carried out using NEB Turbo or DH5α cells (New England Biolabs).

Electrocompetent strain preparation {#S10}
-----------------------------------

The previously described strains S1030^[@R9]^ and S2060^[@R11]^ were used in all luciferase and plaque assays, as well as in PACE experiments. The glycerol stock of either strain was used to seed a 2-mL overnight culture using 2xYT media (United States Biological) supplemented with 10 μg/mL tetracycline (Sigma Aldrich), 50 μg/mL streptomycin (Sigma Aldrich), 10 μg/mL fluconazole (TCI America), and 10 μg/mL amphotericin B (TCI America) in a 37 °C shaker at 230 rpm. The saturated culture was diluted 1,000-fold in 50 mL of the same supplemented media and grown under identical conditions until it reached mid log-phase (OD~600~ 0.5--0.8). Once the appropriate OD~600~ was reached, the cells were pelleted in a 50-mL conical tube (VWR) centrifuged at 10,000 *G* for 5 min at 4 °C. The supernatant was immediately decanted and the interior of the tube was wiped with a few Kimwipes (Kimberly-Clark) to remove residual media and salts. The cells were resuspended in 25 mL of pre-chilled, sterile filtered 10% glycerol in MilliQ purified water using a pipette to quickly break up the pellet. The cells were centrifuged and washed an additional three times. After the last centrifugation step, the interior of the tube was wiped with a few Kimwipes to remove residual glycerol solution. The pellet was resuspended in as little volume as possible, typically \~150 μL, and split into 10 μL aliquots for storage. Cells were flash frozen using a liquid N~2~ bath, then quickly transferred to −80°C for extended storage. Electrocompetent S1030 or S2060 cells produced by this method typically yielded 10^7^--10^8^ colonies/μg plasmid DNA and enable the simultaneous electroporation of up to three plasmids carrying orthogonal origins of replication and antibiotic resistance cassettes to yield transformants containing all plasmids.

General USER cloning {#S11}
--------------------

All plasmid and phage materials were constructed via USER cloning^[@R33]^. See [Extended Data Table 2](#T2){ref-type="table"}. Briefly, primers were designed to include a single internal deoxyuracil base 15--20 bases from the 5′ end of the primer, specifying this region as the "USER junction". Criteria for design of the USER junction were: it should contain minimal secondary structure, have 45 °C \< T~m~ \< 70 °C, and begin with a deoxyadenosine and end with a deoxythymine (to be replaced by deoxyuridine). The USER junction specifies the homology required for correct assembly. We note that PfuTurbo Cx Hotstart DNA polymerase (Agilent Technologies), VeraSeq ULtra DNA polymerase (Enzymatics), or Phusion U Hot Start DNA Polymerase (Life Technologies) are able to use primers carrying deoxyuracil bases, whereas some other polymerases undergo a phenomenon known as PCR poisoning and do not extend the primer.

All PCR products were purified using MinElute PCR Purification Kit (Qiagen) to 10 μL final volume and quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific). For assembly, PCR products carrying complementary USER junctions were mixed in an equimolar ratio (up to 1 pmol each) in a 10 μL reaction containing 15 units *Dpn*I (New England Biolabs), 0.75 units USER (Uracil-Specific Excision Reagent) enzyme (Endonuclease VIII and Uracil-DNA Glycosylase, NEB), 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 100 μg/ml BSA at pH 7.9 (1x CutSmart Buffer, New England Biolabs). The reactions were incubated at 37 °C for 45 min, followed by heating to 80 °C and slow cooling to 22 °C at 0.1 °C/s in a temperature-controlled block. The hybridized constructs were directly used for heat-shock transformation of chemically competent NEB Turbo *E. coli* cells according to the manufacturer's instructions. Transformants were selected on 1.8% agar-2xYT plates supplemented with the appropriate antibiotic(s).

For SP cloning, the hybridized constructs were purified using EconoSpin purification columns (Epoch Life Sciences), eluted using 25 μL 10% glycerol, and transformed into electrocompetent S2060 cells carrying the phage-responsive AP pJC175e, which produces functional pIII in response to phage infection (this strain is henceforth referred to as S2208). Following recovery for 3--4 h at 37 °C using 2xYT (United States Biological) media, the culture was centrifuged and the supernatant was purified using a 0.22 μm PVDF Ultrafree centrifugal filter (Millipore). The supernatant was diluted serially in 100-fold increments and used in plaque assays using log-phase S2208 cells. Following overnight at 37 °C, single plaques were picked into 2xYT media and grown for 12--18 h in a 37 °C shaker at 230 rpm. The supernatant was purified again to yield clonal phage stocks. In all cases, cloned plasmids and phages were prepared using the TempliPhi 500 Amplification Kit (GE Life Sciences) according to the manufacturers protocol and verified by Sanger sequencing.

Plaque assays {#S12}
-------------

S1030^[@R9]^ or S2060^[@R11]^ cells transformed with the AP of interest were grown in 2xYT (United States Biological) liquid media supplemented with the appropriate antibiotics to an OD~600~ of 0.6--0.9. The phage supernatant was diluted serially in three, 100-fold increments to yield four total samples (undiluted, 10^2^-fold, 10^4^-fold, and 10^6^-fold diluted) to be used for infections. For each sample, 150 μL of cells were added to 10 μL of phage that had been filtered using a 0.22 μm PVDF Ultrafree centrifugal filter (Millipore). Within 1--2 min of infection, 1 mL of warm (\~55°C) top agar (7 g/L bacteriological agar in 2xYT) was added to the phage/cell mixture, mixed by pipetting up and down once, and plated onto quartered plates that had been previously poured with 2 mL of bottom agar (18 g/L bacteriological agar in 2xYT) in each quadrant. The plates were then grown overnight at 37 °C before plaques could be observed.

Phage-Assisted Continuous Evolution (PACE) {#S13}
------------------------------------------

Host cell cultures, lagoons, media, and the PACE apparatus were as previously described^[@R9]^. Recombined selection phage harboring gene III (rSP) will poison a PACE experiment by outcompeting the evolving SP. We have noted that the likelihood of rSP occurrence in an SP stock increases with extended standing culture growth during the initial SP stock preparation. To reduce the likelihood of rSP formation, all SPs are repurified prior to any continuous evolution experiments. Briefly, SPs were plaqued on S2208 cells. A single plaque was picked into 2 mL 2xYT (United States Biological) supplemented with the appropriate antibiotics and grown until the culture reached mid log-phase (OD~600~ 0.5--0.8). The culture was centrifuged using a tabletop centrifuge for 2 min at 10,000 *G*, followed by supernatant filtration using a 0.22 μm PVDF Ultrafree centrifugal filter (Millipore). This short growth period routinely yields titers of 10^6^--10^8^ pfu/mL and was found to minimize the occurrence of rSP during PACE experiments.

To prepare the PACE strain, the AP and MP were co-transformed into electrocompetent S1030 cells (see above) and recovered using Davis rich media^[@R9]^ (DRM) to ensure MP repression. Transformations were plated on 1.8% agar-2xYT containing 50 μg/mL carbenicillin, 40 μg/mL chloramphenicol, 10 μg/mL fluconazole, 10 μg/mL amphotericin B, 100 mM glucose (United States Biological) and grown for 12--18 h in a 37 °C incubator. Following overnight growth, four single colonies were picked and resuspended in DRM, then serially diluted and plated on 1.8% agar-2xYT containing 50 μg/mL carbenicillin, 40 μg/mL chloramphenicol, 10 μg/mL fluconazole, 10 μg/mL amphotericin B, and either 100 mM glucose or 100 mM arabinose (Gold Biotechnology) and grown for 12--18 h in a 37 °C incubator. Concomitant with this plating step, the dilution series was used to inoculate liquid cultures in DRM supplemented with 50 μg/mL carbenicillin, 40 μg/mL chloramphenicol, 10 μg/mL tetracycline, 50 μg/mL streptomycin, 10 μg/mL fluconazole, 10 μg/mL amphotericin B and grown for 12--18 h in a 37 °C shaker at 230 rpm. Following confirmation of arabinose sensitivity using the plate assay, cultures of the serially diluted colonies still in log-phase growth were used to seed a 25-mL starter culture for the PACE chemostat.

Once the starter culture had reached log-phase density (OD~600~ 0.5--0.8), the 25-mL culture was added directly to 175 mL of fresh DRM in the chemostat. The chemostat culture was maintained at 200 mL and grown at a dilution rate of 1.5--1.6 vol/hr as previously described^[@R9]^. Lagoons flowing from the chemostats were maintained at 40 mL, and diluted as described for each experiment. Lagoons were supplemented with 25 mM arabinose to induce the MP for 8--16 h prior to infection with packaged SP. Samples were taken at the indicated time points, centrifuged at 10,000 *G* for 2 min, then filtered with a 0.2 μm filter and stored overnight at 4°C. Phage aliquots were titered by plaque assay on S2208 cells (total phage titer) and S1030 or S2060 cells (rSP titer) for all time points.

Mutagenesis during PACE {#S14}
-----------------------

The basal mutation rate of replicating filamentous phage in *E. coli* (7.2×10^−7^ substitutions/bp/generation) is sufficient to generate all possible single but not double mutants of a given gene in a 40-mL lagoon following one generation of phage replication. For the 2,139 bp *rpoZ-Cry1Ac* target, a basal mutation rate of 7.2×10^−7^ substitutions/bp/generation applied to 2×10^10^ copies of the gene (a single generation) in a 40-mL lagoon yields \~3.1×10^7^ base substitutions, easily enough to cover all 6,417 single point mutants but not all double mutants. Arabinose induction of our first generation mutagenesis plasmid (MP), MP1, increased the phage mutation rate by \~100-fold, yielding 7.2×10^−5^ substitutions/bp/generation, yielding \~3.1×10^9^ substitutions spread over 2×10^10^ copies of the gene after a single generation. This enhanced mutation rate is sufficient to cover all possible single mutants (6.4×10^3^ possibilities) and double mutants (4.1×10^7^ possibilities), but no triple mutants (2.6×10^11^ possibilities) after a single phage generation. Our recent efforts to enhance mutagenesis in PACE yielded the improved MP6 system^[@R12]^, which increases the phage mutation rate by an additional 100-fold as compared to MP1, resulting in 7.2×10^−3^ substitutions/bp/generation, yielding \~3.1×10^11^ substitutions spread over 2×10^10^ copies of the gene after a single generation. This elevated mutation rate is sufficient to cover all possible single mutants (6.4×10^3^ possibilities), double mutants (4.1×10^7^ possibilities), and many triple mutants (2.6×10^11^ possibilities) after a single phage generation.

Luciferase assays {#S15}
-----------------

Complementary plasmids (CPs) were co-transformed with an AP of interest into electrocompetent S1030^[@R9]^ or S2060^[@R11]^ cells and plated onto 1.8% agar-2xYT plates with 50 μg/mL carbenicillin and 100 μg/mL spectinomycin. After overnight growth at 37 °C, single colonies were each picked into 2 mL DRM supplemented with 50 μg/mL carbenicillin, 100 μg/mL spectinomycin, 10 μg/mL tetracycline, 50 μg/mL streptomycin, 10 μg/mL fluconazole, 10 μg/mL amphotericin B and grown for 12--18 h in a 37 °C shaker at 230 rpm. Following overnight growth, cultures were diluted 1000-fold in a 96-well deep well plate containing 500 μL DRM with 50 μg/mL carbenicillin, 100 μg/mL spectinomycin and the indicated arabinose, IPTG or anhydrotetracycline (ATc) concentration to induce protein expression from either the AP or CP. Constitutive APs and CPs were used where no inducer concentration is given. After growth with shaking at 37 °C for 4--5 hours, 150 μL of each culture was transferred to a 96-well black wall, clear bottom plate (Costar), and the OD~600~ and luminescence for each well was measured on an Infinite M1000 Pro microplate reader (Tecan). The OD~600~ of a well containing only media was subtracted from all sample wells to obtain a corrected OD~600~ value for each well. The raw luminescence value for each well was then divided by that well's corrected OD~600~ value to obtain the luminescence value normalized to cell density. Each variant was assayed in at least biological triplicate, and the error bars shown reflect the standard deviations of the independent measurements.

High-throughput sequencing and oligotype analysis {#S16}
-------------------------------------------------

Raw reads are deposited in the NCBI Sequence Read Archive with accession number PRJNA293870, and all custom scripts used in analysis are available at <http://github.com/MonsantoCo/BadranEtAl2015>. Illumina reads obtained from each time point were mapped to the SP055-rpoZ-cMyc-Cry1Ac1-d123 reference sequence using bowtie v2.1.0^[@R34]^, and the resulting SAM files were combined into a single BAM file using samtools v0.1.19^[@R35]^. This BAM file was used as input to freebayes v0.9.21-12-g92eb53a^[@R36]^ to call SNPs, using the command "freebayes \--use-best-n-alleles 1 \--pooled-continuous \--use-reference-allele \--theta 500000000 \--min-alternate-fraction 0.01 \--ploidy 1 \--region SP055-rpoZ-cMyc-Cry1Ac1-d123:2833-4971." The analysis is encapsulated in the custom script "ill.callsnps.sh." PacBio polymerase reads were demultiplexed with RS_Resequencing_Barcode.1 workflow provided by PacBio. Polymerase reads with quality score lower than 0.80 (defined by the PacBio scoring algorithm) or shorter than 50bp were filtered. High quality reads were processed into subreads after sequencing primers and adaptors were removed. Circular consensus reads (or reads-of-inserts) were obtained by calling consensus of subreads generated from the same polymerase reads. These circular consensus reads were mapped to the SP055-rpoZ-cMyc-Cry1Ac1-d123 reference sequence using BLASR v1.3.1.142244^[@R37]^, and the alignment was exported as an aligned FASTA sequence using the custom script "SAMtoAFA.py." The aligned FASTA was used as input to the oligotyping platform^[@R22]^, manually specifying entropy components as the positions at which the Illumina data defined informative SNPs. Only oligotypes that occur at \>1% in at least one sample were retained. This methodology resulted in informative changes at 25 of the 27 specified components. Oligotypes with gaps at the specified components, likely due to indels in the PacBio sequencing or alignment, were reassigned to other oligotypes with nucleotides in those positions only when it could be done unambiguously, and discarded otherwise, resulting in a total fraction abundance \< 1 in [Fig. 5D](#F5){ref-type="fig"}. The resulting oligotype-percent abundance matrix was read into R and analyzed using the custom script "PedigreeAndMullerPlot.R." The pedigree was refined manually, assuming that single-mutant derivatives of previous oligotypes are due to *de novo* mutation, while double, triple, or greater mutations that can be explained by recombination of previously observed oligotypes was due to recombination, since the latter are highly unlikely to arise by multiple point mutation after the start of the PACE experiment.

High-throughput primary *Bt* toxin preparation and analysis {#S17}
-----------------------------------------------------------

Wild-type *Cry1Ac* was cloned into the *Bt* expression vector pMON262346 using BspQ1 endonuclease restriction sites. Consensus PACE-evolved *Cry1Ac* variants were synthesized (Gen9) and cloned into the *Bt* expression vector pMON262346 using Hot Fusion^[@R32]^. Reversion mutants of consensus Cry1Ac PACE variants were generated via PCR with Phusion High-Fidelity DNA polymerase (New England Biolabs) and mutant primers followed by Hot Fusion into the *Bt* expression vector pMON262346. The resulting plasmids were transformed into the protease-deficient *Bt* strain EG10650^[@R38]^ for protein expression. Cells were grown from single colonies in 96-well plates (Thermo Scientific, AB-0932) overnight in 400 μL Brain Heart Infusion Glycerol (BHIG) media (VWR) supplemented with 5 μg/mL chloramphenicol. Overnight cultures were used to prepare glycerol stocks (15% glycerol final concentration) and stored at −80 °C for future protein expression. Following overnight growth, 10 μL of each culture was used to inoculate 1 mL of complete *C2* medium^[@R39]^ containing 5 μg/mL chloramphenicol in 96-well plates. The plates were incubated at 26 °C with vigorous shaking at 550 rpm in a Multitron shaking incubator (Infors HT) for 72 hr. The cells were harvested by centrifugation at 3,200 *G* for 15 min at 4 °C. The supernatant was decanted and a single 3.5 mm glass bead was added to each well of the plate. The pellet was then resuspended in 1 ml of TX wash buffer composed of 10 mM Tris-HCl, pH 7.5, 0.005% Triton X-100 supplemented with 25 units/mL Benzonase® (EMD Millipore), and 2 mM MgCl~2~, incubated at room temperature for 30--60 min (with vigorous vortexing every 10 min), then centrifuged at 3,200 *G* for 15 min at 4 °C. The resulting pellet was resuspended and centrifuged under identical conditions two additional times.

The washed spore/crystal pellet from each 1-mL culture was solubilized in the 96-well plate using 300 μL of solubilization buffer composed of 50 mM CAPS, pH 11, and 10 mM DTT, then incubated while shaking at room temperature for 1 h. The insoluble debris was pelleted by centrifugation at 3,200 *G* for 15 min at 4 °C, and 200 μL of the supernatant were transferred to a sterile U-bottom 96-well plate. To each well, 10 μL of 0.2 mg/mL trypsin in 1 M Tris-HCl, pH 7.5 was added. The mixture was incubated at 37°C for 2 h while shaking at 150 rpm, followed by quenching using 2 μL 0.1 M PMSF. The solution was filtered using a Millipore multiscreen plate with a 0.22 μm membrane. Protein stability was assessed by SDS-PAGE and quantified using spot densitometry. Proteins purified using this protocol were tested in downstream insect cell assays.

Secondary *Bt* toxin purification and analysis {#S18}
----------------------------------------------

*Bt* glycerol stocks described above were used for large-scale protein expression and purification. A 2-mL starter culture of BHIG medium supplemented with 5 μg/mL chloramphenicol was inoculated from the glycerol stocks and grown overnight at 280 rpm in a 28°C shaker. The following day, the saturated culture was transferred into 500 mL complete C2 medium containing 5 μg/mL chloramphenicol in a 2 L baffled flask and grown for an additional 72 h at 26°C while shaking at 280 rpm. Sporulation and crystal formation in the culture was verified by optical microscopy of a 2-μL aliquot of the saturated *Bt* culture. Upon confirmation of crystals, the partially lysed sporulated cells were harvested by centrifugation at 10,000 *G* for 12 min at 4°C. The pellet was then resuspended in 100 mL TX wash buffer composed of 10 mM Tris-HCl, pH 7.5, and 0.005% Triton X-100 supplemented with 0.1 mM PMSF, 25 units/mL Benzonase® (Sigma-Aldrich), and 2 mM MgCl~2~, incubated at room temperature for 30--60 min (with vigorous vortexing every 10 min), then centrifuged at 3,200 *G* for 15 min at 4°C. The resulting pellet was resuspended and centrifuged under identical conditions two additional times.

The washed spore/crystal pellet was solubilized in 120 mL 50 mM CAPS, pH 11, 10 mM DTT at room temperature for 1 h while shaking at 130 rpm. The solubilized protein was separated from the insoluble debris by centrifugation at 35,000 *G* for 20 min at 4 °C. The supernatant was transferred to a fresh flask, and then supplemented with 10 mL 0.2 mg/mL Trypsin in 1 M Tris-HCl at pH 7.5. The mixture was incubated at 30 °C for 2--6 h with shaking at 150 rpm and trypsinization was monitored by SDS-PAGE. Once the trypsin digestion reaction was complete, the mixture was centrifuged at 3,200 *G* for 15 min at 4 °C. The clear supernatant was removed and mixed with PMSF to 1 mM final concentration. The sample was loaded on a 5--10 mL Q-Sepharose (GE Healthcare) anion exchange column at a flow-rate of 4 mL/min and the trypsin resistant core of the toxin was eluted in 25 mM sodium carbonate, pH 9 supplemented with 200--400 mM NaCl. Fractions containing the toxin tryptic cores were pooled, concentrated (Millipore Amicon Ultra-15 centrifugal filter Units, Fisher) and loaded on a Hiload Superdex 200 gel filtration column using an ÄKTA chromatography system (GE Healthcare, United Kingdom). The column was pre-equilibrated and run with 25 mM sodium carbonate at pH 10.5 supplemented with 1 mM β-mercaptoethanol. Only the monomer peak of the toxin fractions was collected in each case and concentrated to 1--3 mg/mL. The final protein concentration was quantified by spot densitometry. The quality of the trypsinized toxin was assessed using the peptide mass fingerprinting (PMF) method that was based on in-gel digestion of proteins by trypsin and mass spectrometry (MS) analysis of the resulted peptides.

*T. ni* receptor fragment expression and purification {#S19}
-----------------------------------------------------

Custom expression vectors pMON251427 and IS0008 (same as pMON251427 but with wild-type TnCAD) were used to express TnTBR3 and TnCAD fragments in *Escherichia coli.* Both vectors contain an N-terminal MBP-TVMV protease cleavage site tag^[@R40]^ and a C-terminal 6x histidine tag flanking the receptor fragment of interest, with the ORF driven by the T7 promoter. Expression vectors were transformed into commercial BL21 (λDE3) competent cells (Life Technologies) that had been previously transformed with TVMV protease expression vector (pMON101695; encodes constitutive TVMV protease from a pACYC184 (New England Biolabs) backbone). A single colony was inoculated in 2 mL of LB media supplemented with 50 μg/mL kanamycin and 25 μg/mL chloramphenicol, and grown at 37°C for 4 h to generate a starter culture, which was used to prepare glycerol stocks and stored at −80°C for the future protein expression. A second starter culture was inoculated using the BL21 (λDE3) strain glycerol stocks in 2 mL of LB media supplemented with 50 μg/mL kanamycin and 25 μg/mL chloramphenicol and grown in a 25°C shaker (280 rpm) for 15 h. The culture was transferred into 500 mL of Terrific Broth medium (24g/L yeast extract, 12 g/L tryptone, and 5 g/L glucose) supplemented with 50 μg/mL kanamycin and 25 μg/mL chloramphenicol, and grown at 37 °C for 4 h at 280 rpm, then transferred to 15 °C and grown for and additional 48 h after supplementation with IPTG to a final concentration of 0.1 mM.

The cells were harvested by centrifugation at 10,000 *G* for 12 min at 4 °C. The bacterial cell pellet was resuspended in affinity buffer A (25 mM Tris-HCl at pH 8.0, 0.5 M NaCl, 15 mM imidazole, and 0.2 mM CaCl~2~) containing 125 units/mL of Benzonase (EMD Millipore), 10,000 units/mL of Chicken egg white lysozyme (Sigma Aldrich) and 1x BugBuster (Novagen). The cell slurry was incubated at room temperature for 15 min, followed by sonication using Cell Disruptor W-0375 (Heat Systems-Ultrasonics) at 45% Duty Cycle (output No.5) for 30 seconds with 60 second rests for a total of three cycles. The cell lysate was centrifuged at 35,000 *G* for 20 min at 4°C. The supernatant was loaded onto a 5-mL Ni-NTA column that had been pre-equilibrated using affinity buffer A. After extensive washing with affinity buffer A, the receptor fragment was eluted with the affinity buffer B (25 mM Tris-HCl at pH 8.0, 0.1 M NaCl, 250 mM imidazole, 0.2 mM CaCl~2~). Fractions containing the receptor fragment were pooled, concentrated and loaded on a Hiload Superdex 200 gel filtration column using an ÄKTA chromatography system (GE Healthcare, United Kingdom). The column was pre-equilibrated and run with 25 mM Tris-HCl at pH 8.0, 0.1 M NaCl, 0.2 mM CaCl~2~. Dimer and monomer peaks of the *T. ni* TBR3 and CAD fractions were collected separately and concentrated to 1--2 mg/mL. Only TnTBR3 and TnCAD monomers were used for Cry1Ac1 binding studies.

Fluorescence thermal shift (FTS) assays {#S20}
---------------------------------------

All assays were performed using a BioRad CFX96 real-time PCR thermal cycler, enabling thermal manipulations and dye fluorescence detection. The fluorescence sensitive dye SYPRO orange (Life Technologies, S6650) was used at a 5x concentration in all assays. The temperature was increased by 0.5 °C each cycle over a temperature range of 25--90 °C. Assay reactions were performed in 96-well white PCR plates (Bio-Rad, No. HSP9631), and heat-sealed (Thermo Scientific, No. ALPS3000) to reduce volume loss through evaporation. The data was analyzed using the CFX manager software.

Protein--protein interaction affinity measurement {#S21}
-------------------------------------------------

The Octet^Qk^ (ForteBio) and the Dip and Read^™^ Ni-NTA (NTA) biosensors were used to measure the affinity of Cry1Ac and its variants to immobilized 6xHis-TnCAD or TnTBR3 receptor fragments in 25 mM Tris-HCl at pH 8.5, 0.1 M NaCl, 0.1 mg/ml BSA, 0.05% Tween 20 according to the manufacturer's instructions. Octet Data Acquisition 7.1.0.100 software was used for data acquisition, and ForteBio Data Analysis 7 software was used for data analysis. At least four readings at different Cry1Ac1 concentrations (2--100 nM) were used for each receptor fragment-Bt toxin interaction and a global fit was used to calculate binding affinities.

Insect cell assays {#S22}
------------------

Sf9 cells (Life Technologies) were plated in Sf-900^™^ III SFM (Life Technologies) at a density of 50,000 cells/well in a 96-well optical bottom black plate (Nunc, Thermo Scientific). The cells were incubated at 27 °C overnight to allow for adherence to the plate. Following overnight incubation, the medium was aspirated from the cells and 100 μL of p3 or p4 generation (third or fourth generation of baculovirus amplification in Sf9 cells following initial transfection with plasmid) recombinant baculovirus encoding each receptor diluted in SFM was added to each well. The plates were kept in a humidified environment to prevent evaporation and incubated at 27 °C for 48 h. Receptor expression was confirmed by western blotting. Toxins were diluted to the same protein concentration in 25 mM sodium carbonate at pH 11, supplemented with 1 mM β-mercaptoethanol, followed by an additional 10-fold dilution in unsupplemented Grace's Media with 2 μM SYTOX Green Nucleic Acid Stain (Life Technologies, S7020). The media was removed from the wells without disturbing the attached cells, and the diluted toxins or buffer controls were added to respective wells. The fluorescence was measured on a CLARIOstar microplate reader (BMG Labtech) after incubation for 4 h. The fluorescence intensity of control cells expressing β-glucuronidase (GUS) was subtracted from wells expressing the variable receptor fragments with or without toxins. Replicates were averaged and signal was plotted for each toxin condition.

Primary insect diet bioassays {#S23}
-----------------------------

Insect diet bioassays using the evolved consensus Cry1Ac variants were performed as previously described^[@R41]^. Briefly, 200 mL of artificial diet in 96-well plates were overlaid with 20 mL aliquots of toxin Bt spore/crystal or Bt crystal suspension, dried, after which wells were infested with neonate insect eggs suspended in 0.2% agar, dried again, sealed with Mylar sheets, and incubated at 20 °C, 60% RH, in complete darkness for 5 days. The plates were scored on day 5 for larval mortality and growth stunting. Each assay was carried out in three independent biological replicates with eight insects per replicate.

Secondary insect diet bioassays {#S24}
-------------------------------

An inbred Bt-susceptible laboratory strain of *T. ni*, (designated the Cornell strain)^[@R42]^, and a Cry1Ac-resistant strain nearly isogenic to the Cornell strain, GLEN-Cry1Ac-BCS^[@R28]^, were maintained on a wheat germ-based artificial diet at 27 °C with 50% humidity and a photoperiod of 16 h light and 8 h dark^[@R42]^. Diet surface overlay bioassays were conducted to determine the insecticidal activity of the toxins in the susceptible and Cry1Ac-resistant *T. ni*, as previously described^[@R42]^. Briefly, 200 μL of toxin solution was spread on the surface of 5 mL of artificial diet in 30-mL plastic rearing cups (diet surface area was \~7 cm^2^), and 10 neonatal larvae were placed into each rearing cup after the toxin solution had dried. For each bioassay, 7--8 concentrations of the toxin were used and each treatment included five replicates (50 larvae total per concentration). Larval growth inhibition (neonates that did not reach 2^nd^ instar after 4 days) and mortality were recorded after 4 days of feeding. The observed larval growth inhibition and mortality were corrected using Abbott's formula^[@R43]^. Both IC~50~ and LC~50~ values and their 95% confidence intervals were calculated by probit analysis using the computer program POLO (LeOra Softare, 1997).

Extended Data {#S25}
=============

![Bacterial 2-hybrid component validation and optimization\
**a,** Plasmids encoding an IPTG-inducible *λcI-SH2* cassette ("DBD") and an ATc-inducible activator-HA4 cassette ("activator") were co-transformed into the *E. coli* S1030 host strain and induced using either or both small molecules. T4 AsiA-mediated transcriptional activation required low-level expression of the σ70 (R541C/F563Y/L607P) mutant to alleviate AsiA toxicity. Use of RpoZ as the activation domain showed the greatest degree of transcriptional activation (\~17-fold). **b,** DNA-binding domain variation shows that multivalent phage repressors yield a greater degree of transcriptional activation than the monomeric zinc finger Zif268. **c,** Transcriptional activation from a combination of the λcI DNA binding domain and RpoZ transcriptional activator was evaluated using a number of previously evolved protein-protein interactions involving either monobodies or DARPins, showing the generality of binding interaction detection. Error bars reflect the standard deviation of at least three independent biological replicates.](nihms772405f6){#F6}

![Optimization of the P~lacZ~ promoter for improved sensitivity and dynamic range\
**a,** Promoter and DNA-binding domain combinations tested during P~lacZ~ optimization, showing uninduced and induced levels of OD-normalized luminescence. The SH2/HA4 interaction pair was used in all cases. The fold activation in each case was calculated as the ratio of the induced and uninduced luciferase expression signals. **b,** Graphical representation of the data in part (**a**), showing the wide distribution of promoter background levels and degrees of transcriptional activation. In both (A) and (B), the red and green dots indicate the starting (P~lac62~) and final (P~lacZ-opt~) promoter/DNA-binding domain combinations, respectively. Each data point in (**b**) reflects the average of at least three independent biological replicates.](nihms772405f7){#F7}

![Bacterial 2-hybrid optimization\
**a,** Inducer titration of the interacting fusion proteins driving the 2-hyrbid system. The black and green lines represent the uninduced (0 μM IPTG) and induced (1 μM IPTG) levels of IPTG-inducible *434cI-SH2* expression, while ATc induces expression of the *rpoZ-HA4* cassette. In subsequent graphs and assays, the expression level resulting from the IPTG-inducible P~lac~ promoter was measured by Western blot and approximated using a constitutive promoter to reduce experimental variability. **b,** The degree of transcriptional activation using HA4 monobody mutants correlated with known binding affinities. The highest levels of activation resulted from K~d~ = low nM affinities, while weak affinities in the K~d~ = low μM range could still be detected. **c,** The relationship between DNA-binding domain multivalency state (monomeric, dimeric or tetrameric DNA-binding domain fused to the SH2 domain) and transcriptional activation resulting from the SH2/HA4 interaction, with higher multivalency states yielding greater activation levels. **d,** RBS modification enables robust modulation of the relative activation levels from the P~lacZ-opt~ promoter using the SH2/HA4 interaction. **e,** Operator-promoter binding site spacing strongly affects transcriptional activation levels. 434cI binding at 61 base pairs upstream of the P~lacZ-opt~ promoter resulted in the most robust activation. **f,** Linker extension to include one, two, or three G~4~S motifs result in reduced activation levels using the SH2/HA4 interacting pair. **g,** Phage plaque formation as a function of target protein multivalency. "No operator" indicates a scrambled 434cI operator control AP, and "phage control" indicates an AP in which the phage shock promoter (activated by phage infection) drives gene III expression. **h,** Co-crystal structure of the ABL1 SH2 (blue) bound to the HA4 monobody (red), highlighting the interaction of HA4 Y87 (red spheres) with key residues of the phosophotyrosine-binding pocket (blue spheres) of the SH2 domain (PDB 3K2M). The phosphate ion is shown in orange at the interaction interface. **i,** Apparent binding activity of mutants of the HA4 monobody at position 87. Tyrosine, tryptophan and phenylalanine are tolerated at position 87 and enable protein-protein interaction by bacterial 2-hybrid assay. Error bars throughout this figure reflect the standard deviation of at least three independent biological replicates.](nihms772405f8){#F8}

![Choice of Cry1Ac and TnTBR3 fragments used in PACE\
**a,** Protein sequence alignment of known Cry1Ac-binding motifs from cadherin receptors in a number of lepidopteran species, as well as the cadherin receptor from *Trichoplusia ni* (TnCAD). The toxin-binding region (TBR; shown in red) of the known Cry1Ac-binding motifs differs from TnCAD at seven positions (shown in blue). Mutation of three residues in the TnCAD TBR (M1433F, L1436S, and D1437A) to resemble the corresponding positions of the cadherin-receptor TBRs yielded the evolutionary stepping-stone target TnTBR3. **b,** Schematic representations of the Cry1Ac and *T. ni* TBR3/CAD full-length receptors and fragments tested in this study. The red stars in the TnTBR3 variants represent the three mutations introduced into TnCAD to generate TnTBR3. **c,** Transcriptional activation assay using Cry1Ac and TnTBR3 fragments shows that the greatest degree of transcriptional activation resulted from full-length Cry1Ac together with TBR3 fragment 3 (TnTBR3-F3). RpoZ-Cry1Ac and 434cI-TnTBR3 fusions were used in all cases. **d,** Overnight phage enrichment assays using selection phages (SPs) that encode either kanamycin resistance (Kan^R^) only or Kan^R^ together with RpoZ-Cry1Ac. Compared to the Kan^R^-only SP, the RpoZ-Cry1Ac SP enriches \> 26,000-fold overnight. **e,** Continuous propagation assays in the PACE format using either the Kan^R^-only SP or the RpoZ-Cry1Ac SP show that the moderate affinity of Cry1Ac for TnTBR3 allows phage propagation at low flow rates (≤ 1.5 lagoon vol/h).](nihms772405f9){#F9}

![Single-clone sequencing and evolved Cry1Ac characterization following PACE using the bacterial 2-hybrid luminescence reporter\
**a,** Coding mutations of the tested RpoZ-Cry1Ac clones at the end of each of the four segments of PACE. Consensus mutations are colored according to the segment in which they became highly enriched in the population ([Fig. 3*a*](#F3){ref-type="fig"}). Mutations colored in black were observed at low abundance (≤ 5% of sequenced clones). **b,** Mutational dissection of the consensus mutations from the first segment of PACE reveals the requirement for both D384Y and S404C to achieve high-level transcriptional activation using the TnTBR3-F3 target. Mutations listed in red occurred in the RpoZ activation domain, whereas mutations listed in blue occurred in the Cry1Ac domain. Error bars reflect the standard deviation of at least three independent biological replicates. **c,** Structure of wild-type Cry1Ac (PDB: 4ARX) showing the positions of the evolved consensus mutations. The colors correspond to the PACE segments shown in [Fig. 3](#F3){ref-type="fig"} during which the mutations became highly abundant.](nihms772405f10){#F10}

![High-throughput DNA sequencing of PACE Cry1Ac selection phage libraries\
The number of reads mapped to the wt *rpoZ-Cry1Ac* reference sequence using (**a**) Pacific Biosciences (PacBio) or (**b**) Illumina sequencing. Time points are colored according to the corresponding segment of the PACE experiment ([Fig. 3A](#F3){ref-type="fig"}). **c,** In general, the majority of PacBio reads aligned to the wt *rpoZ-Cry1Ac* reference sequence were found to cluster around \~2,200 base pairs, corresponding to the size of the full-length fusion gene and indicating high-quality sequencing reads. **d,** Illumina high-throughput sequencing yielded a number of high quality SNPs across all time points. The corresponding mutations are shown in (**e**).](nihms772405f11){#F11}

![Insect diet bioassay activity of PACE-evolved Cry1Ac variants against various agricultural pests\
Two consensus and three stabilized PACE-evolved Cry1Ac variants were tested for activity in eleven pests: **a,** C*hrysodeixis includes* (soybean looper); **b,** *Heliothis virescens* (tobacco budworm); **c,** *Helicoverpa zea* (corn earworm); **d,** *Plutella* xylostella (diamondback moth); **e,** *Agrotis ipsilon* (black cutworm); **f,** *Spodoptera frugiperda* (fall armyworm); **g,** *Anticarsia gemmatalis* (velvetbean caterpillar); **h,** *Diatraea saccharalis* (sugarcane borer); *Spodoptera eridania* (southern armyworm); *Leptinotarsa decemlineata* (Colorado potato beetle); and *Lygus lineolaris* (tarnished plant bug). Stabilized variants showed enhanced activity in *C. includens* and *H. virescens* as compared to wild-type Cry1Ac, and comparable activity to wild-type Cry1Ac in *H. zea*, *P. xylostella*, *A. ipsilon*, *S. frugiperda*, *A. gemmatalis*, and *D. saccharalis*. No activity was observed for any of the Cry1Ac variants at any tested dose for *S. eridania*, *L. decemlineata* or *L. lineolaris*. No insect larvae mortality was observed for *S. frugiperda*, although high toxin doses greatly stunted growth.](nihms772405f12){#F12}

![Comparison of cadherin receptor sequence identity\
The % sequence identity using the full-length cadherin receptor (**a**) or fragment used for directed evolution experiments (**b**) for insects tested in Extended Data Figure 8. Numbers in parenthesis denote the number of identical amino acids between the two receptors. In general, mortality and stunting data from diet bioassays correlates with cadherin receptor sequence identity.](nihms772405f13){#F13}

###### Insect bioassays against susceptible and resistant *Trichoplusia ni*

The median lethal concentration (LC~50~) and media inhibitory concentration (IC~50~) were determined using 7--8 concentrations of the indicated toxins in an insect diet surface overlay bioassay using either Cry1Ac-susceptible or Cry1Ac-resistant *Trichoplusia ni* neonatal larvae. In each case, the 95% confidence interval (95% CI), the slope of the best fit (Slope) and the standard error (SE) is given. The relative potency (%) has been normalized to the activity of wild-type Cry1Ac for each case.

  ------------------------- --------------- ------------------ ------------------ ------------ ----------- -------------------------- --------------------------
  **Susceptible *T. ni***   **Mortality**   **Toxin**          **LC~50~ (ppm)**   **95% CL**   **Slope**   **SE**                     **Relative potency (%)**
                                                                                                                                      
  Cry1Ac                    0.039           0.019--0.069       2.54               0.26         100                                    
  Cry1Ac-C03                0.793           0.505--1.082       2.84               0.41         5                                      
  Cry1Ac-C05                0.715           0.407--1.176       1.78               0.22         5                                      
  Cry1Ac-C03s               0.018           0.014--0.020       4.68               0.75         217                                    
  Cry1Ac-C05s               0.035           0.026--0.045       3.59               0.41         111                                    
  Cry1Ac-A01s               0.021           0.015--0.024       4.82               1.09         186                                    
                                                                                                                                      
  **Growth inhibition**     **Toxin**       **IC~50~ (ppm)**   **95% CL**         **Slope**    **SE**      **Relative potency (%)**   
                                                                                                                                      
  Cry1Ac                    0.019           0.011--0.027       3.09               0.39         100                                    
  Cry1Ac-C03                0.136           0.110--0.160       4.00               0.62         14                                     
  Cry1Ac-C05                0.217           0.167--0.268       2.59               0.32         9                                      
  Cry1Ac-C03s               0.007           0.003--0.010       3.65               0.61         271                                    
  Cry1Ac-C05s               0.016           0.014--0.018       5.53               0.82         119                                    
  Cry1Ac-A01s               0.005           0.004--0.006       4.92               0.9          380                                    
                                                                                                                                      
  **Resistant *T. ni***     **Mortality**   **Toxin**          **LC~50~ (ppm)**   **95% CL**   **Slope**   **SE**                     **Relative potency (%)**
                                                                                                                                      
  Cry1Ac                    51.229          9.929--90.241      1.89               0.36         100                                    
  Cry1Ac-C03                408.713         263.629--680.973   0.81               0.1          13                                     
  Cry1Ac-C05                235.698         79.467--510.323    1.12               0.15         22                                     
  Cry1Ac-C03s               1.841           1.390--2.312       2.25               0.28         2783                                   
  Cry1Ac-C05s               1.938           1.550--2.352       2.55               0.29         2643                                   
  Cry1Ac-A01s               0.153           0.046--0.289       2.01               0.22         33483                                  
                                                                                                                                      
  **Growth inhibition**     **Toxin**       **IC~50~ (ppm)**   **95% CL**         **Slope**    **SE**      **Relative potency (%)**   
                                                                                                                                      
  Cry1Ac                    23.402          4.587--46.512      1.49               0.25         100                                    
  Cry1Ac-C03                56.626          40.600--75.685     1.84               0.21         41                                     
  Cry1Ac-C05                47.232          20.236--90.729     1.16               0.12         50                                     
  Cry1Ac-C03s               0.733           0.515--0.949       2.06               0.28         3193                                   
  Cry1Ac-C05s               1.116           0.797--1.484       2.19               0.23         2097                                   
  Cry1Ac-A01s               0.083           0.061--0.104       2.57               0.38         28195                                  
  ------------------------- --------------- ------------------ ------------------ ------------ ----------- -------------------------- --------------------------

###### Plasmids used in this work

Each plasmid is defined by the plasmid class, antibiotic resistance, origin of replication, and promoter/gene combinations describing the relevant ORFs carried by the plasmid. Relevant figures where these materials were used are given in each case.

  Plasmid name   Class (resistance)   Origin of replication   ORF 1                       ORF 2                                 ORF 3      Figure(s)                                                   
  -------------- -------------------- ----------------------- --------------------------- ------------------------------------- ---------- ----------------------- -------- -------------------------- --------------------------------------------------------------------------------------------------------------------------------
  pAB029f        CP (spec^R^)         ColEI                   P~lacZ~                     λcI-SH2~ABL1~                         P~lacIq~   lacI                    \-       \-                         [S1A, S1C](#SD1){ref-type="supplementary-material"}
  pAB030g        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoA-HA4                \-       \-                         [S1A](#SD1){ref-type="supplementary-material"}
  pAB031a        CP (spec^R^)         ColEI                   P~lacZ~                     HA4-Zif268                            P~lacIq~   lacI                    \-       \-                         [S1B](#SD1){ref-type="supplementary-material"}
  pAB035a        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoZ-SH2~ABL1~          \-       \-                         [S1B](#SD1){ref-type="supplementary-material"}
  pAB035h        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoZ-HA4                \-       \-                         [S1A, S1C](#SD1){ref-type="supplementary-material"}
  pAB042a        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoZ-YSX1               \-       \-                         [S1C](#SD1){ref-type="supplementary-material"}
  pAB042b        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoZ-MBPoff7            \-       \-                         [S1C](#SD1){ref-type="supplementary-material"}
  pAB042d        AP (carb^R^)         SC101                   P~lac62~                    gIII, luxAB                           P~tet~     rpoZ-p38_2\_3           \-       \-                         [S1C](#SD1){ref-type="supplementary-material"}
  pAB043a        CP (spec^R^)         ColEI                   P~lacZ~                     λcI-MBP                               P~lacIq~   lacI                    \-       \-                         [S1C](#SD1){ref-type="supplementary-material"}
  pAB043c        CP (spec^R^)         ColEI                   P~lacZ~                     λcI-p38α                              P~lacIq~   lacI                    \-       \-                         [S1C](#SD1){ref-type="supplementary-material"}
  pAB045a        CP (spec^R^)         ColEI                   P~lacZ~                     rpoZ-HA4                              P~lacIq~   lacI                    \-       \-                         [S1B](#SD1){ref-type="supplementary-material"}, [S3A, S3C](#SD1){ref-type="supplementary-material"}
  pAB049b        CP (spec^R^)         ColEI                   P~lacZ~                     HA4-AsiA                              P~lacIq~   lacI                    \-       \-                         [S1A](#SD1){ref-type="supplementary-material"}
  pAB051e        AP (carb^R^)         SC101                   P~Ext-10consλop-62~         gIII, luxAB                           P~tet~     λcI-SH2~ABL1~           P~lpp~   rpoD (R541C/F563Y/L607P)   [S1A](#SD1){ref-type="supplementary-material"}
  pAB060c        AP (carb^R^)         SC101                   P~lac62~                    luxAB                                 P~pro1~    λcI-SH2~ABL1~           \-       \-                         [S1B](#SD1){ref-type="supplementary-material"}
  pAB061i        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4                              P~lacIq~   lacI                    \-       \-                         [2A](#F2){ref-type="fig"}, [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i10      CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4 (Y87R)                       P~lacIq~   lacI                    \-       \-                         [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i11      CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4 (Y87K)                       P~lacIq~   lacI                    \-       \-                         [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i2       CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4 (Y87A)                       P~lacIq~   lacI                    \-       \-                         [2A](#F2){ref-type="fig"}, [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i3       CP (spec^R^)         ColEI                   P~pro1~                     rpoZ                                  P~lacIq~   lacI                    \-       \-                         [2A](#F2){ref-type="fig"}, [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i8       CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4 (Y87W)                       P~lacIq~   lacI                    \-       \-                         [S4B](#SD1){ref-type="supplementary-material"}
  pAB061i9       CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-HA4 (Y87F)                       P~lacIq~   lacI                    \-       \-                         [S4B](#SD1){ref-type="supplementary-material"}
  pAB064d        AP (carb^R^)         SC101                   P~lac62~                    luxAB                                 P~pro1~    434cI-SH2~ABL1~         \-       \-                         [S1B](#SD1){ref-type="supplementary-material"}
  pAB076i3       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           gIII, luxAB                           P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2B](#F2){ref-type="fig"}
  pAB076i5       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2+3)       gIII, luxAB                           P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2B](#F2){ref-type="fig"}
  pAB076i6       AP (carb^R^)         SC101                   P~lacZ-opt~ (no operator)   gIII, luxAB                           P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2B](#F2){ref-type="fig"}
  pAB076i7       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           gIII, luxAB                           P~pro1~    434cI(RR69)-SH2~ABL1~   \-       \-                         [2B](#F2){ref-type="fig"}
  pAB078d10      AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~pro1~    434cI(RR69)-SH2~ABL1~   \-       \-                         [2A](#F2){ref-type="fig"}, [S3C](#SD1){ref-type="supplementary-material"}
  pAB078d3       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2A](#F2){ref-type="fig"}, [S3B, S3C](#SD1){ref-type="supplementary-material"}, [S4B](#SD1){ref-type="supplementary-material"}
  pAB078d5       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~pro1~    434cI                   \-       \-                         [2A](#F2){ref-type="fig"}
  pAB078d7       AP (carb^R^)         SC101                   P~lacZ-opt~ (off-target)    luxAB                                 P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2A](#F2){ref-type="fig"}
  pAB078d8       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2)         luxAB                                 P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2A](#F2){ref-type="fig"}, [S3C](#SD1){ref-type="supplementary-material"}
  pAB078d9       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2+3)       luxAB                                 P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2A](#F2){ref-type="fig"}
  pAB082a        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d123                      \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082b        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d3                        \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082c        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d2A                       \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082d        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d2B                       \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082e        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d2C                       \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082f        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d23A                      \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082g        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d23B                      \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB082h        CP (spec^R^)         ColEI                   P~pro1~                     rpoZ-Cry1Ac-d23C                      \-         \-                      \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB085c        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~tet~     434cI-TnTBR3-FL         \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB085d        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~tet~     434cI-TnTBR3-F3         \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB085d6       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~pro1~    434cI-TnTBR3-F3         \-       \-                         [3B](#F3){ref-type="fig"}
  pAB085d7       AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~pro1~    434cI-TnCAD-F3          \-       \-                         [3C](#F3){ref-type="fig"}
  pAB085e        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           luxAB                                 P~tet~     434cI-TnTBR3-F7         \-                                  [S5C](#SD1){ref-type="supplementary-material"}
  pAB088c        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           gIII, luxAB                           P~pro1~    434cI-TnTBR3-F3         \-       \-                         [3A](#F3){ref-type="fig"}
  pAB088e        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2)         gIII, luxAB                           P~pro1~    434cI-TnTBR3-F3         \-       \-                         [3A](#F3){ref-type="fig"}
  pAB088h        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2)         gIII, luxAB                           P~pro1~    434cI-TnCAD-F3          \-       \-                         [3A](#F3){ref-type="fig"}
  pAB088i        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           gIII, luxAB                           P~pro1~    434cI(RR69)-TnCAD-F3    \-       \-                         [3A](#F3){ref-type="fig"}
  pAB092a        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1+2)         gIII, luxAB                           P~pro1~    434cI-SH2~ABL1~         \-       \-                         [2B](#F2){ref-type="fig"}
  pAB094a        CP (spec^R^)         ColEI                   P~BAD~                      rpoZ-HA4                              P~C~       araC                    \-       \-                         [S3B](#SD1){ref-type="supplementary-material"}
  pAB094b        CP (spec^R^)         ColEI                   P~BAD~                      rpoZ-HA4 (Y35A)                       P~C~       araC                    \-       \-                         [S3B](#SD1){ref-type="supplementary-material"}
  pAB094c        CP (spec^R^)         ColEI                   P~BAD~                      rpoZ-HA4 (R38A)                       P~C~       araC                    \-       \-                         [S3B](#SD1){ref-type="supplementary-material"}
  pAB094d        CP (spec^R^)         ColEI                   P~BAD~                      rpoZ-HA4 (E52A)                       P~C~       araC                    \-       \-                         [S3B](#SD1){ref-type="supplementary-material"}
  pAB094e        CP (spec^R^)         ColEI                   P~BAD~                      rpoZ-HA4 (Y87A)                       P~C~       araC                    \-       \-                         [S3B](#SD1){ref-type="supplementary-material"}
  pAB107a        AP (carb^R^)         SC101                   P~lacZ-opt~ (OR1)           gIII, luxAB                           P~pro1~    434cI                   \-       \-                         [2B](#F2){ref-type="fig"}
  pJC175e        AP (carb^R^)         SC101                   P~PSP~                      gIII, luxAB                           \-         \-                      \-       \-                         [2B](#F2){ref-type="fig"}
  SP013          SP (kan^R^)          M13f1                   P~gIII~                     rpoZ                                  \-         \-                      \-                                  [S5D, S5E](#SD1){ref-type="supplementary-material"}
  SP055          SP (kan^R^)          M13f1                   P~gIII~                     rpoZ-Cry1Ac                           \-         \-                      \-                                  [3A](#F3){ref-type="fig"}, [S5D, S5E](#SD1){ref-type="supplementary-material"}
  SP096          SP (none)            M13f1                   P~gIII~                     rpoZ-HA4                              \-         \-                      \-       \-                         [2B](#F2){ref-type="fig"}
  SP097          SP (none)            M13f1                   P~gIII~                     rpoZ-HA4 (Y87A)                       \-         \-                      \-       \-                         [2B](#F2){ref-type="fig"}
  SP098          SP (none)            M13f1                   P~gIII~                     rpoZ                                  \-         \-                      \-       \-                         [2B](#F2){ref-type="fig"}
  MP4            MP (chlor^R^)        CloDF13                 P~BAD~                      dnaQ926, dam, seqA                    P~C~       araC                    \-       \-                         [3A](#F3){ref-type="fig"}
  MP6            MP (chlor^R^)        CloDF13                 P~BAD~                      dnaQ926, dam, seqA, emrR, ugi, cda1   P~C~       araC                    \-       \-                         [3A](#F3){ref-type="fig"}
  pMON101647     EP (chlor^R^)        ColEI                   P~T7~                       (none)                                \-         \-                      \-       \-                         \-
  pMON101695     EP (chlor^R^)        P15A                    P~T7~                       MBP-TVMV                              \-         \-                      \-       \-                         \-
  pMON133051     EP (chlor^R^)        ColEI                   P~T7~                       Cry1Ac                                \-         \-                      \-       \-                         \-
  pMON251427     EP (kan^R^)          ColEI                   P~T7~                       TnTBR3-FL                             \-         \-                      \-       \-                         \-
  IS0008         EP (kan^R^)          ColEI                   P~T7~                       TnCAD-FL                              \-         \-                      \-       \-                         \-
  pMON262346     EP (chlor^R^)        ColEI                   P~T7~                       Cry1Ac                                \-         \-                      \-       \-                         \-
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![Protein-binding phage-assisted continuous evolution (PACE)\
**a,** Anatomy of a phage-infected host cell during PACE. The host *E. coli* cell carries two plasmids: the accessory plasmid (AP)^[@R6]^, which links protein binding to phage propagation and controls selection stringency, and the mutagenesis plasmid (MP)^[@R6],[@R12]^, which enables arabinose-inducible elevated level mutagenesis during PACE. **b,** Following infection, selection phage (SP) that encode an evolving protein capable of binding to the target protein induces expression of gene III from the AP, resulting in the production of pIII, a phage protein required for progeny phage produced by that host cell to infect subsequent host cells. PACE takes place in a fixed-volume vessel (the "lagoon") that is continuously diluted with fresh host cells. Only those SP encoding proteins that bind the target can propagate faster than they are diluted out of the lagoon.](nihms772405f1){#F1}

![Protein-binding PACE selection development and stringency modulation\
**a**, The relationship between target protein multivalency and transcriptional output measured by luciferase expression. The number of ABL1 SH2 domains available to bind the HA4 monobody was modulated by varying the 434cI DNA-binding domain multivalency state (1x, 2x, 4x, or 6x SH2). "No operator" indicates a scrambled 434cI operator control AP. **b,** During PACE, the inactive monobody mutant HA4~Y87A~ was subjected to no mutagenesis (MP not induced), enhanced mutagenesis (MP induced with arabinose), or enhanced mutagenesis with genetic drift (MP induced with arabinose in addition to an initial period of zero selection stringency), then selected for binding to the ABL1 SH2 target protein. **c,** The combination of drift and enhanced mutagenesis during PACE (green line) resulted in the evolution of Tyr and Trp residues at position 87, either of which restores SH2-binding activity, while no mutagenesis (red line) or enhanced mutagenesis without drift (blue line) resulted in phage washout. Error bars in (**a**) reflect the standard deviation of at least three independent biological replicates.](nihms772405f2){#F2}

![Continuous evolution of Cry1Ac variants that bind the *Trichoplusia ni* cadherin receptor\
**a,** PACE was executed in four segments. The first two segments implemented the designed TnTBR3-F3 "stepping-stone" target under intermediate levels of mutagenesis (MP4). The final two segments implemented the final TnCAD-F3 target under high levels of mutagenesis (MP6). Phage titer (colored lines) and lagoon flow rate (grey lines) are shown at all sampled time points. The dotted lines indicate transfer of evolving phage to a new lagoon fed by the host cell culture corresponding to the next segment of PACE. **b, c,** Transcriptional activation assays using 434cI-TnTBR3-F3 (**b**) or 434cI-TnCAD-F3 (**c**) and individual RpoZ-Cry1Ac variants evolved during PACE, compared to wild-type RpoZ-Cry1Ac (wt). **d,** Oligotyping analysis of lagoon samples during PACE based on high-throughout DNA sequencing data. Oligotypes containing high frequency mutations (≥ 1%) are represented by different polygons, colored based on the stage in which they first became abundant in the evolving Cry1Ac gene pool. Mutations in Cry1Ac for each oligotype are shown in the table. Numbers in parentheses indicate the oligotype number assigned to that mutant following a synonymous (silent) mutation. **e,** Plausible evolution trajectories over the entire PACE experiment derived from oligotyping analysis strongly suggests instances of recombination during PACE, and also reveals the influence of mutation rate, selection stringency, and target protein on evolutionary outcomes. The colors and numbers in each circle correspond to those in (**d**).](nihms772405f3){#F3}

![Characterization of consensus evolved Cry1Ac variants\
**a,** Consensus evolved Cry1Ac mutant sequences, including the D384Y/S404C double mutant (DM) that enabled TnTBR3-F3 recognition during the first segment of PACE. **b,** SDS-PAGE analysis of Cry1Ac variants following trypsin digestion, revealing proteolytic instability of consensus evolved variants. S = solubilized crude Bt crystals; T = trypsin-treated. **c,** Toxicity assays using Sf9 cells expressing the ABCC2 (black) or TnCAD receptor (green). Cells were incubated with Cry1Ac variants following trypsin digestion at the concentrations of activated toxin shown. Cry1Ac-induced cell permeabilization causes a fluorescent dye to enter cells, resulting in an increase in fluorescence. The evolved Cry1Ac variants, but not wild-type Cry1Ac, induce permeabilization of cells expressing TnCAD. Error bars reflect the standard deviation of at least three independent biological replicates. **d,** Insect larvae diet bioassays using wild-type and evolved consensus Cry1Ac variants, showing the loss of evolved Cry1Ac potency in insect larvae arising from impaired stability.](nihms772405f4){#F4}

![Characterization of stabilized evolved Cry1Ac variants reveals potently enhanced activity\
**a,** Sequence, thermal stability, and TnCAD target-binding affinity of unstable and stabilized PACE evolved consensus mutants. **b,** SDS-PAGE analysis of trypsin digestion reactions showing dramatically enhanced stability upon D384Y and S404C reversion. S = solubilized crude Bt crystals; T = trypsin-treated. **c,** Toxicity assays using Sf9 cells overexpressing the ABCC2 (black) or TnCAD receptor (green), demonstrating maintained activity of stabilized variants against both ABCC2 or TnCAD. All variants were used at 10 ppm. Error bars reflect the standard deviation of at least three independent biological replicates. **d, e,** Highly purified wild-type Cry1Ac, evolved consensus variants, or stabilized evolved variants were added to the diets of Cry1Ac-susceptible (**d**) or Cry1Ac-resistant (**e**) *T. ni* larvae at the indicated doses. Stabilized evolved variants moderately enhance mortality in Cry1Ac-susceptible larvae compared to wild-type Cry1Ac. Stabilized evolved variants greatly outperform wild-type Cry1Ac toxin in killing Bt toxin-resistant *T. ni* larvae.](nihms772405f5){#F5}
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